• Skip to content
  • Skip to footer
  • Accessibility options
University of Brighton
  • About us
  • Business and
    employers
  • Alumni and
    supporters
  • For
    students
  • For
    staff
  • Accessibility
    options
Open menu
Home
Home
  • Close
  • Study here
    • Get to know us
    • Why choose Brighton?
    • Explore our prospectus
    • Chat to our students
    • Ask us a question
    • Meet us
    • Open days and visits
    • Virtual tours
    • Applicant days
    • Meet us in your country
    • Campuses
    • Our campuses
    • Our city
    • Accommodation options
    • Our halls
    • Helping you find a home
    • What you can study
    • Find a course
    • Full A-Z course list
    • Explore our subjects
    • Our academic departments
    • How to apply
    • Undergraduate application process
    • Postgraduate application process
    • International student application process
    • Apprenticeships
    • Transfer from another university
    • International students
    • Clearing
    • Funding your time at uni
    • Fees and financial support
    • What's included in your fees
    • Brighton Boost – extra financial help
    • Advice and guidance
    • Advice for students
    • Guide for offer holders
    • Advice for parents and carers
    • Advice for schools and colleges
    • Supporting you
    • Your academic experience
    • Your wellbeing
    • Your career and employability
  • Research
    • Research and knowledge exchange
    • Research and knowledge exchange organisation
    • The Global Challenges
    • Centres of Research Excellence (COREs)
    • Research Excellence Groups (REGs)
    • Our research database
    • Information for business
    • Community University Partnership Programme (CUPP)
    • Postgraduate research degrees
    • PhD research disciplines and programmes
    • PhD funding opportunities and studentships
    • How to apply for your PhD
    • Research environment
    • Investing in research careers
    • Strategic plan
    • Research concordat
    • News, events, publications and films
    • Featured research and knowledge exchange projects
    • Research and knowledge exchange news
    • Inaugural lectures
    • Research and knowledge exchange publications and films
    • Academic staff search
  • About us
  • Business and employers
  • Alumni, supporters and giving
  • Current students
  • Staff
  • Accessibility
Search our site
A pink ribbon, looped in the shape for the iconographic support symbol for breast cancer sufferers.
Research and knowledge exchange
  • Research and knowledge exchange
  • Postgraduate research degrees
  • Research features
  • Research organisation
  • Research environment
  • Research features
  • Features
  • Breast cancer management and patient choice. PefHER.

PrefHER: putting patient choice and preferences at the forefront of breast cancer management

Approximately one in five patients diagnosed with breast cancer worldwide will have HER2-positive (HER2+) breast cancer, a particularly aggressive form of the disease. HER2+ breast cancer patients require treatment via the targeted anti-HER2 monoclonal antibody agent, trastuzumab following surgery, chemotherapy and radiotherapy.  

This demands hospital attendance for intravenous administration via a cannula, an in situ port, or line, 3 times weekly for 12 months. Intravenous administration is inconvenient and can take several hours exerting a considerable physical and emotional burden, limiting patients’ ability to resume normal life. In 2013 NICE approved a new subcutaneous formulation of trastuzumab with similar efficacy and safety as its intravenous counterpart, but with an administration time of just five minutes. In the wider clinical context patient preference is a key factor when drugs or administration methods have similar efficacy and safety properties. Taking patient preference into account helps to ensure optimal treatment adherence and improves the patient experience and satisfaction with treatment.  

Find out more about the work of Professor Dame Lesley Fallowfield

Measuring patient preference for subcutaneous or intravenous HER2 positive breast cancer treatment

Professor Dame Lesley Fallowfield and colleagues at the Sussex Health Outcomes Research and Education in Cancer Centre (SHORE-C) have pioneered a body of research on Psycho-Oncology with a particular focus on patient preference and health professionals’ communication skills with patients, especially those with cancer. The team is also leading the field in assessing patients’ quality of life in cancer trials including the MRC/NIHR funded UK Collaborative Trial of Ovarian Cancer Screening.

Brighton and Sussex Medical School (BSMS) researchers, led by Professor Dame Lesley Fallowfield, designed, conducted and analysed study-specific patient interview schedules used in the international clinical trial, PrefHER, to measure patient preference for subcutaneous or intravenous HER2+ breast cancer treatment. The findings of the PrefHER study were pivotal to the regulatory approval of trastuzumab subcutaneous by the Australian Therapeutic Goods Administration in 2015 and the US Federal Drug Administration in 2019, thus opening the route to market in these countries.

For the trials, patients had the trastuzumab administered first subcutaneously and then switched to intravenous, or vice-versa. Fallowfield and colleagues at SHORE-C led the development, optimisation and implementation of the study-specific patient interviews in each participating country. Two sets of interviews were carried out, one before patient randomization, and one after the treatment cycles. The PrefHER study was global and yet, irrespective of culture, the primary outcome was the same, with patients expressing a strong and compelling preference for subcutaneous delivery. 

Patient preference studies such as PrefHER can serve as a powerful tool to engage patients and their communities. Moreover, it can quantify the patient voice across different stages of clinical drug development, drug regulatory approval and care management to support patient-centric, healthcare decision-making. By revealing an overwhelming preference for its subcutaneous route of administration. This finding contributed to the market approval of trastuzumab subcutaneous by the US Food and Drug Administration (FDA) and its Australian counterpart. In practice, it also provided the research evidence to support the delivery of cancer treatments closer to the patient’s home– a central tenet of the NHS Five Year Forward plan for improvement in outcomes for cancer patients.  

As part of its multi-disciplinary review and evaluation of the application, the FDA commented on the robustness of the SHORE-C led interview methods and approved product labelling that refers to the PrefHER trial data to support the Patient Experience.

 

Further examples of research excellence at the University of Brighton

  • Can stress cause cancer?

    Can stress cause cancer?

  • Improving childhood asthma and eczema treatment.

    Improving childhood asthma and eczema treatment.

  • Research to improve outcomes relating to liver disease and liver cancer

    Research to improve outcomes relating to liver disease and liver cancer

  • Research leads to improved WHO and UNICEF sanitation guidance.

    Research leads to improved WHO and UNICEF sanitation guidance.

  • Preventing strokes and heart attacks in the over 80s.

    Preventing strokes and heart attacks in the over 80s.

  • Sexual health research: understanding HIV and improving health among men who have sex with men

    Sexual health research: understanding HIV and improving health among men who have sex with men

  • Communities of Practice and Value Creation Frameworks: how do we learn from each other?

    Communities of Practice and Value Creation Frameworks: how do we learn from each other?

Back to top
  • Facebook
  • X logo
  • Instagram
  • TikTok
  • YouTube
  • LinkedIn icon

Contact us

University of Brighton
Mithras House
Lewes Road
Brighton
BN2 4AT

Main switchboard 01273 600900

Course enquiries

Sign up for updates

University contacts

Report a problem with this page

Quick links Quick links

  • Courses
  • Open days
  • Explore our prospectus
  • Academic departments
  • Academic staff
  • Professional services departments
  • Jobs
  • Privacy and cookie policy
  • Accessibility statement
  • Libraries
  • Term dates
  • Maps
  • Graduation
  • Site information
  • Online shop
  • The Student Contract

Information for Information for

  • Current students
  • International students
  • Media/press
  • Careers advisers/teachers
  • Parents/carers
  • Business/employers
  • Alumni/supporters
  • Suppliers
  • Local residents